Troy Cox, former CEO of Foundation Medicine, is Chairman of Sophia Genetics, Vice Chairman at LetsGetChecked, and Independent Board Director at Zymeworks and BioSplice as well as non-profits MassBio and Dream Foundation.
Mr. Cox was President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche valuing FMI at $5.3 billion. Prior to Foundation Medicine, Mr. Cox served as Senior Vice President and Officer at Genentech, where he led US BioOncology for a period of unprecedented growth to over $12 billion, participating in the launch of nearly half of the products from the world’s oncology leader, while accountable to help steer the Roche Genentech R&D portfolio. Before Genentech, Mr. Cox held executive and senior roles of increasingly broad accountabilities including President UCB BioPharmaceuticals, Senior Vice President Sanofi-Aventis and diverse foundational roles at Schering-Plough.
Mr. Cox received his MBA at the University of Missouri and BBA in Finance from the University of Kentucky.